New drug HX111 targets advanced cancers in early trial
NCT ID NCT07333469
First seen Jan 12, 2026 · Last updated May 04, 2026 · Updated 14 times
Summary
This study tests a new drug called HX111 in people with advanced solid tumors or lymphoma that has not responded to other treatments. The trial has two parts: first, finding the safest dose, and then checking how well it works. About 70 adults aged 18 to 70 with a life expectancy of at least 3 months can join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR AND LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.